The economic burden of visual impairment and blindness: a systematic review

被引:150
作者
Koeberlein, Juliane [1 ]
Beifus, Karolina [1 ]
Schaffert, Corinna [1 ]
Finger, Robert P. [2 ,3 ]
机构
[1] Univ Wuppertal, Dept Hlth Econ & Hlth Care Management, Wuppertal, Germany
[2] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[3] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia
来源
BMJ OPEN | 2013年 / 3卷 / 11期
基金
英国医学研究理事会;
关键词
Visual Impairment; Blindness; Cost of Illness; Health Economics; COST-OF-ILLNESS; VISION LOSS; HEALTH-CARE; MEDICARE BENEFICIARIES; PERSONAL COSTS; OLDER-ADULTS; IMPACT; INDIVIDUALS; DEPRESSION; SEVERITY;
D O I
10.1136/bmjopen-2013-003471
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview. Design Systematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. Eligibility criteria for included studies Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included. Methods We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment. Results A total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12175-14029 for moderate visual impairment, US$ PPP 13154-16321 for severe visual impairment and US$ PPP 14882-24180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1h/week (or US$ PPP 55062) for persons with vision 20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses. Conclusions VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B.
引用
收藏
页数:14
相关论文
共 47 条
[1]   COST OF ILLNESS STUDIES IN HEALTH-CARE - A COMPARISON OF 2 CASES [J].
AMENT, A ;
EVERS, S .
HEALTH POLICY, 1993, 26 (01) :29-42
[2]  
[Anonymous], PHARMACOECONOMICS
[3]  
[Anonymous], HLTH POL DAT OECD HL
[4]  
[Anonymous], COEFFICIENT KAPPA SO
[5]  
[Anonymous], GDP DEFL WORLD DEV I
[6]   Usefulness of US cost-of-illness studies in healthcare decision making [J].
Bloom, BS ;
Bruno, DJ ;
Maman, DY ;
Jayadevappa, R .
PHARMACOECONOMICS, 2001, 19 (02) :207-213
[7]   Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma [J].
Bramley, Thomas ;
Peeples, Patti ;
Walt, John G. ;
Juhasz, Marta ;
Hansen, Jan E. .
ARCHIVES OF OPHTHALMOLOGY, 2008, 126 (06) :849-856
[8]   Prevalence and burden of self-reported blindness, low vision, and visual impairment in the french community -: A nationwide survey [J].
Brézin, AP ;
Lafuma, A ;
Fagnani, F ;
Mesbah, M ;
Berdeaux, G .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (08) :1117-1124
[9]   Methods for measuring personal costs associated with vision impairment [J].
Chou, Shiao-Lan ;
Lamoureux, Ecosse ;
Keeffe, Jill .
OPHTHALMIC EPIDEMIOLOGY, 2006, 13 (06) :355-363
[10]   The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) [J].
Clarke, P ;
Gray, A ;
Legood, R ;
Briggs, A ;
Holman, R .
DIABETIC MEDICINE, 2003, 20 (06) :442-450